

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code : 2666)

CONTINUING CONNECTED TRANSACTIONS

EXCEEDED THE ANNUAL CAP

References are made to the announcements (the “**Announcements**”) of the Company dated 23 November 2023 and 28 October 2025 in relation to, among other things, the continuing connected transactions under the 2024 Medical Related Product Procurement Framework Agreement and the annual caps and revised annual caps thereunder. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

EXCEEDED THE ANNUAL CAP

In the course of finalising the annual results of the Group for the year ended 31 December 2025, the Company discovered that the continuing connected transactions under the 2024 Medical Related Product Procurement Framework Agreement have exceeded the annual cap for the year ended 31 December 2025. Based on the financial information of the Company, as of 31 December 2025, the actual amounts incurred by the Group to GT-PRC and/or its associates totaling RMB547.8338 million, exceeding the annual cap of RMB365.00 million which had been previously set by the Company.

The Board has resolved to ratify the actual incurred amounts of RMB547.8338 million for the year ended 31 December 2025 under the 2024 Medical Related Product Procurement Framework Agreement.

REASONS FOR EXCEEDING THE ANNUAL CAP

The actual amounts paid by the Group to GT-PRC and/or its associates under the 2024 Medical Related Product Procurement Framework Agreement for the year ended 31 December 2025 exceeded the annual cap primarily due to errors arising from internal statistical processing.

ENHANCED INTERNAL CONTROL MEASURES

In order to ensure the Company's compliance with the applicable Listing Rules requirements going forward and with a view to preventing such event from re-occurring, the Company has taken the following measures to further enhance and strengthen its internal control in respect of its continuing connected transactions:

- (i) the Company will enhance the reporting and monitoring procedures in respect of the transaction amounts of connected transactions, and improve the processes and frequency of data collection and cross-checking, so as to ensure that the transaction amounts do not exceed the relevant annual caps or any applicable exemption thresholds;
- (ii) the Company will closely monitor the aggregated transaction amounts under the relevant documents entered into on a monthly basis. By relying on information platforms such as the contract management system and finance shared system, the Company will track the monthly submission and implementation of procurement budgets and funding plans of connected persons, regularly obtain and monitor connected transaction data, and exercise control over the limits for connected transactions from the source. If the actual transaction amounts reach 70% of the disclosed annual caps at any time during the year, the Company will immediately commence the assessment for revising the annual caps and comply with the relevant requirements for announcement and/or independent Shareholders' approval requirements under the Listing Rules;
- (iii) the Company has arranged specialized training on connected transactions for relevant personnel, covering the requirements regarding connected transactions under the Listing Rules and the interpretation of the transaction documents;
- (iv) a list of connected persons will be regularly identified and maintained, and mandatory checks against this list will be conducted by the Company prior to entering into any transaction;
- (v) the Company's external auditors will conduct an annual review of the pricing and the annual caps of the transactions contemplated under the relevant agreements;
- (vi) the independent non-executive Directors will conduct an annual review of the implementation and enforcement of the transactions to ensure, among other things, that the internal control policies and measures are effectively implemented; and
- (vii) the Company will consult legal counsel and the Stock Exchange in respect of potential connected transactions.

INFORMATION OF THE PARTIES

The Company

The Company is a healthcare-focused listed company controlled by a central state-owned enterprise, which was listed on the Stock Exchange in July 2015 with GT-PRC as its controlling shareholder. The Company has long been committed to the rapidly developing healthcare industry in China. Built on comprehensive medical services, featured by specialty medical services, powered by health technology, and supported by financial services, the Company fully leverages the strengths of industry-finance integration to build a win-win and shared comprehensive healthcare ecosystem, and strives to become a trustworthy world-class healthcare group.

GT-PRC

GT-PRC was established in March 1998 as a state-owned enterprise supervised by the State-owned Assets Supervision and Administration Commission. The principal business of GT-PRC comprises three major segments, namely, advanced manufacturing and technology service, pharmaceutical and healthcare and trade and engineering contracting.

LISTING RULES IMPLICATIONS

As at the date of this announcement, GT-PRC directly and indirectly holds approximately 37.66% of the issued share capital of the Company and is a controlling shareholder of the Company. According to Rule 14A.07 of the Listing Rules, GT-PRC and its associates are connected persons of the Company.

Accordingly, the transactions between the Group and GT-PRC and/or its associates under the 2024 Medical Related Product Procurement Framework Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As the actual incurred amounts exceeded the annual cap, the Company is required to re-comply with the relevant requirements under Chapter 14A of the Listing Rules in order to ratify the breach. As one or more of the applicable percentage ratios of the actual incurred amounts for the year ended 31 December 2025 exceeds 0.1% but is less than 5%. Therefore, the actual incurred amounts for the year ended 31 December 2025 under the 2024 Medical Related Product Procurement Framework Agreement constitutes non-exempt continuing connected transactions of the Company subject to the reporting, annual review and announcement requirements but exempt from the Independent Shareholders' approval requirements pursuant to Chapter 14A of the Listing Rules.

As at the date of this announcement, among the Directors, Mr. Tong Chaoyin and Mr. Lin Chunhai hold positions in GT-PRC or its associates and accordingly they are considered to have material interests in the 2024 Medical Related Product Procurement Framework Agreement. Mr. Tong Chaoyin and Mr. Lin Chunhai had abstained from voting on the resolution at the Board meeting. Save as disclosed above, no Director has interests in the transactions under such framework agreement.

The Directors (including the independent non-executive Directors, but excluding Mr. Tong Chaoyin and Mr. Lin Chunhai) are of the view that the transactions under the 2024 Medical Related Product Procurement Framework Agreement have been, and will continue to be, conducted (i) in the ordinary and usual course of the business of the Company; (ii) on normal commercial terms;

and (iii) on terms that are fair and reasonable and in the interest of the Company and its Shareholders as a whole.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

“2024 Medical Related Product Procurement Framework Agreement”	the medical related product procurement framework agreement entered into between the Company and GT-PRC on 23 November 2023
“associate(s)”	has the meaning ascribed to it under the Listing Rules
“Board”	the board of Directors of the Company
“Company”	Genertec Universal Medical Group Company Limited (通用環球醫療集團有限公司), a company incorporated in Hong Kong with limited liability and the issued shares of which are listed on the main board of the Stock Exchange (stock code: 2666)
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“controlling shareholder”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“GT-PRC”	China General Technology (Group) Holding Company Limited (中國通用技術(集團)控股有限責任公司), a state-owned enterprise and a controlling shareholder of the Company
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC” or “China”	the People’s Republic of China
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholders”	holder(s) of the shares of the Company

“Shares”	the ordinary share(s) in the capital of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary”	has the meaning ascribed to it under the Listing Rules
“%”	per cent

By order of the Board
Genertec Universal Medical Group Company Limited
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Beijing, PRC, 18 March 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Tong Chaoyin, Mr. Lin Chunhai, Mr. Huang Youjie and Mr. Ma Wanming; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.